Development of vaccine against Streptococcus suis infection in pig

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F22%3AN0000245" target="_blank" >RIV/00027162:_____/22:N0000245 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Development of vaccine against Streptococcus suis infection in pig

Popis výsledku v původním jazyce

Development of vaccines against streptococcal infection is challenging due to nature of the interaction between the pathogen and the host immune system. In last decades, vaccines based on conjugates of capsular polysaccharide and carrier protein were proved to be protective against various bacterial pathogens, including streptococcal infections in humans. However, the manufacturing cost is limiting for their use in animals. Although Streptococcus suis infection in pig is currently considered to be one of most important bacterial disease, an effective commercial vaccine is still not available. We thus tested an experimental vaccine against Streptococcus suis serotype 2 based on capsular polysaccharide conjugated to chicken ovalbumin and compared its immunogenicity and protectivity with a vaccine based on CRM197 conjugate. Ovalbumin was selected as a cheap alternative to recombinant carrier proteins widely used in vaccines for human use. We found that the ovalbumin-based experimental vaccine successfully induced immune response in pigs, and the IgG antibody response was even higher than after immunization with capsular polysaccharide CRM197 conjugate. Protectivity of vaccination against infection was evaluated in the challenge experiment and was found promising for both conjugates.

Název v anglickém jazyce

Development of vaccine against Streptococcus suis infection in pig

Popis výsledku anglicky

Development of vaccines against streptococcal infection is challenging due to nature of the interaction between the pathogen and the host immune system. In last decades, vaccines based on conjugates of capsular polysaccharide and carrier protein were proved to be protective against various bacterial pathogens, including streptococcal infections in humans. However, the manufacturing cost is limiting for their use in animals. Although Streptococcus suis infection in pig is currently considered to be one of most important bacterial disease, an effective commercial vaccine is still not available. We thus tested an experimental vaccine against Streptococcus suis serotype 2 based on capsular polysaccharide conjugated to chicken ovalbumin and compared its immunogenicity and protectivity with a vaccine based on CRM197 conjugate. Ovalbumin was selected as a cheap alternative to recombinant carrier proteins widely used in vaccines for human use. We found that the ovalbumin-based experimental vaccine successfully induced immune response in pigs, and the IgG antibody response was even higher than after immunization with capsular polysaccharide CRM197 conjugate. Protectivity of vaccination against infection was evaluated in the challenge experiment and was found promising for both conjugates.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

40301 - Veterinary science

Projekt

<a href="/cs/project/QK1810193" target="_blank" >QK1810193: Moderní metody diagnostiky, terapie a prevence infekcí Streptococcus suis jako nástroj pro sestavování cílených kontrolních programů v chovech prasat</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů